nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—CYP3A5—Teniposide—lymphatic system cancer	0.0957	0.201	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0614	0.129	CbGbCtD
Risperidone—CYP3A7—Vincristine—lymphatic system cancer	0.0614	0.129	CbGbCtD
Risperidone—CYP3A5—Vincristine—lymphatic system cancer	0.0461	0.0969	CbGbCtD
Risperidone—ABCB1—Mitoxantrone—lymphatic system cancer	0.0436	0.0916	CbGbCtD
Risperidone—CYP3A4—Cytarabine—lymphatic system cancer	0.0379	0.0797	CbGbCtD
Risperidone—CYP3A4—Teniposide—lymphatic system cancer	0.0373	0.0785	CbGbCtD
Risperidone—ABCB1—Vincristine—lymphatic system cancer	0.03	0.063	CbGbCtD
Risperidone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0261	0.0549	CbGbCtD
Risperidone—ABCB1—Methotrexate—lymphatic system cancer	0.0182	0.0382	CbGbCtD
Risperidone—CYP3A4—Vincristine—lymphatic system cancer	0.018	0.0378	CbGbCtD
Risperidone—Rash—Teniposide—lymphatic system cancer	0.000409	0.000781	CcSEcCtD
Risperidone—Dermatitis—Teniposide—lymphatic system cancer	0.000409	0.00078	CcSEcCtD
Risperidone—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000407	0.000777	CcSEcCtD
Risperidone—Headache—Teniposide—lymphatic system cancer	0.000407	0.000776	CcSEcCtD
Risperidone—Pruritus—Fludarabine—lymphatic system cancer	0.000404	0.00077	CcSEcCtD
Risperidone—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000403	0.000769	CcSEcCtD
Risperidone—Back pain—Mitoxantrone—lymphatic system cancer	0.000402	0.000768	CcSEcCtD
Risperidone—Leukopenia—Carmustine—lymphatic system cancer	0.0004	0.000764	CcSEcCtD
Risperidone—Anorexia—Bleomycin—lymphatic system cancer	0.000399	0.000761	CcSEcCtD
Risperidone—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000398	0.000758	CcSEcCtD
Risperidone—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000396	0.000755	CcSEcCtD
Risperidone—Anaemia—Vincristine—lymphatic system cancer	0.000395	0.000753	CcSEcCtD
Risperidone—Agitation—Vincristine—lymphatic system cancer	0.000392	0.000749	CcSEcCtD
Risperidone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000392	0.000748	CcSEcCtD
Risperidone—Photosensitivity—Methotrexate—lymphatic system cancer	0.000392	0.000748	CcSEcCtD
Risperidone—Polyuria—Methotrexate—lymphatic system cancer	0.000392	0.000748	CcSEcCtD
Risperidone—Hypotension—Bleomycin—lymphatic system cancer	0.000391	0.000746	CcSEcCtD
Risperidone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00039	0.000745	CcSEcCtD
Risperidone—Convulsion—Carmustine—lymphatic system cancer	0.000388	0.00074	CcSEcCtD
Risperidone—Hypertension—Carmustine—lymphatic system cancer	0.000386	0.000737	CcSEcCtD
Risperidone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000386	0.000736	CcSEcCtD
Risperidone—Nausea—Teniposide—lymphatic system cancer	0.000386	0.000736	CcSEcCtD
Risperidone—Anaemia—Mitoxantrone—lymphatic system cancer	0.000384	0.000733	CcSEcCtD
Risperidone—Vertigo—Vincristine—lymphatic system cancer	0.000384	0.000732	CcSEcCtD
Risperidone—Hepatic failure—Methotrexate—lymphatic system cancer	0.000383	0.00073	CcSEcCtD
Risperidone—Leukopenia—Vincristine—lymphatic system cancer	0.000382	0.000729	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000381	0.000727	CcSEcCtD
Risperidone—Chest pain—Carmustine—lymphatic system cancer	0.000381	0.000727	CcSEcCtD
Risperidone—Myalgia—Carmustine—lymphatic system cancer	0.000381	0.000727	CcSEcCtD
Risperidone—Anxiety—Carmustine—lymphatic system cancer	0.00038	0.000724	CcSEcCtD
Risperidone—Paraesthesia—Bleomycin—lymphatic system cancer	0.000376	0.000717	CcSEcCtD
Risperidone—Malaise—Mitoxantrone—lymphatic system cancer	0.000375	0.000716	CcSEcCtD
Risperidone—Dyspnoea—Bleomycin—lymphatic system cancer	0.000373	0.000711	CcSEcCtD
Risperidone—Renal failure acute—Methotrexate—lymphatic system cancer	0.000373	0.000711	CcSEcCtD
Risperidone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000372	0.00071	CcSEcCtD
Risperidone—Convulsion—Vincristine—lymphatic system cancer	0.00037	0.000706	CcSEcCtD
Risperidone—Hypertension—Vincristine—lymphatic system cancer	0.000369	0.000703	CcSEcCtD
Risperidone—Confusional state—Carmustine—lymphatic system cancer	0.000368	0.000702	CcSEcCtD
Risperidone—Oedema—Carmustine—lymphatic system cancer	0.000365	0.000697	CcSEcCtD
Risperidone—Decreased appetite—Bleomycin—lymphatic system cancer	0.000364	0.000694	CcSEcCtD
Risperidone—Myalgia—Vincristine—lymphatic system cancer	0.000364	0.000694	CcSEcCtD
Risperidone—Cough—Mitoxantrone—lymphatic system cancer	0.000363	0.000692	CcSEcCtD
Risperidone—Infection—Carmustine—lymphatic system cancer	0.000363	0.000692	CcSEcCtD
Risperidone—Vomiting—Fludarabine—lymphatic system cancer	0.000363	0.000692	CcSEcCtD
Risperidone—Convulsion—Mitoxantrone—lymphatic system cancer	0.00036	0.000687	CcSEcCtD
Risperidone—Rash—Fludarabine—lymphatic system cancer	0.00036	0.000686	CcSEcCtD
Risperidone—Dermatitis—Fludarabine—lymphatic system cancer	0.000359	0.000686	CcSEcCtD
Risperidone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000359	0.000685	CcSEcCtD
Risperidone—Pain—Bleomycin—lymphatic system cancer	0.000358	0.000682	CcSEcCtD
Risperidone—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000358	0.000682	CcSEcCtD
Risperidone—Headache—Fludarabine—lymphatic system cancer	0.000357	0.000682	CcSEcCtD
Risperidone—Tachycardia—Carmustine—lymphatic system cancer	0.000356	0.00068	CcSEcCtD
Risperidone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000356	0.000678	CcSEcCtD
Risperidone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000354	0.000676	CcSEcCtD
Risperidone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000354	0.000676	CcSEcCtD
Risperidone—Chest pain—Mitoxantrone—lymphatic system cancer	0.000354	0.000676	CcSEcCtD
Risperidone—Anxiety—Mitoxantrone—lymphatic system cancer	0.000353	0.000673	CcSEcCtD
Risperidone—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000351	0.00067	CcSEcCtD
Risperidone—Lethargy—Methotrexate—lymphatic system cancer	0.000351	0.00067	CcSEcCtD
Risperidone—Discomfort—Mitoxantrone—lymphatic system cancer	0.00035	0.000667	CcSEcCtD
Risperidone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000349	0.000665	CcSEcCtD
Risperidone—Oedema—Vincristine—lymphatic system cancer	0.000349	0.000665	CcSEcCtD
Risperidone—Anorexia—Carmustine—lymphatic system cancer	0.000348	0.000664	CcSEcCtD
Risperidone—Infection—Vincristine—lymphatic system cancer	0.000346	0.000661	CcSEcCtD
Risperidone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000345	0.000658	CcSEcCtD
Risperidone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000344	0.000656	CcSEcCtD
Risperidone—Confusional state—Mitoxantrone—lymphatic system cancer	0.000342	0.000653	CcSEcCtD
Risperidone—Nervous system disorder—Vincristine—lymphatic system cancer	0.000342	0.000652	CcSEcCtD
Risperidone—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000341	0.000651	CcSEcCtD
Risperidone—Hypotension—Carmustine—lymphatic system cancer	0.000341	0.000651	CcSEcCtD
Risperidone—Oedema—Mitoxantrone—lymphatic system cancer	0.000339	0.000648	CcSEcCtD
Risperidone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000339	0.000648	CcSEcCtD
Risperidone—Nausea—Fludarabine—lymphatic system cancer	0.000339	0.000646	CcSEcCtD
Risperidone—Infection—Mitoxantrone—lymphatic system cancer	0.000337	0.000643	CcSEcCtD
Risperidone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000337	0.000643	CcSEcCtD
Risperidone—Shock—Mitoxantrone—lymphatic system cancer	0.000334	0.000637	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000333	0.000635	CcSEcCtD
Risperidone—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000332	0.000634	CcSEcCtD
Risperidone—Urticaria—Bleomycin—lymphatic system cancer	0.000332	0.000634	CcSEcCtD
Risperidone—Anorexia—Vincristine—lymphatic system cancer	0.000332	0.000634	CcSEcCtD
Risperidone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000331	0.000632	CcSEcCtD
Risperidone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000331	0.000631	CcSEcCtD
Risperidone—Insomnia—Carmustine—lymphatic system cancer	0.00033	0.00063	CcSEcCtD
Risperidone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00033	0.000629	CcSEcCtD
Risperidone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000328	0.000626	CcSEcCtD
Risperidone—Paraesthesia—Carmustine—lymphatic system cancer	0.000328	0.000625	CcSEcCtD
Risperidone—Mood swings—Methotrexate—lymphatic system cancer	0.000326	0.000622	CcSEcCtD
Risperidone—Hypotension—Vincristine—lymphatic system cancer	0.000326	0.000621	CcSEcCtD
Risperidone—Dyspnoea—Carmustine—lymphatic system cancer	0.000326	0.000621	CcSEcCtD
Risperidone—Somnolence—Carmustine—lymphatic system cancer	0.000325	0.000619	CcSEcCtD
Risperidone—Anorexia—Mitoxantrone—lymphatic system cancer	0.000324	0.000617	CcSEcCtD
Risperidone—Ataxia—Methotrexate—lymphatic system cancer	0.000324	0.000617	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000318	0.000606	CcSEcCtD
Risperidone—Decreased appetite—Carmustine—lymphatic system cancer	0.000317	0.000606	CcSEcCtD
Risperidone—Hypotension—Mitoxantrone—lymphatic system cancer	0.000317	0.000605	CcSEcCtD
Risperidone—Insomnia—Vincristine—lymphatic system cancer	0.000315	0.000601	CcSEcCtD
Risperidone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000315	0.000601	CcSEcCtD
Risperidone—Paraesthesia—Vincristine—lymphatic system cancer	0.000313	0.000597	CcSEcCtD
Risperidone—Pain—Carmustine—lymphatic system cancer	0.000312	0.000596	CcSEcCtD
Risperidone—Constipation—Carmustine—lymphatic system cancer	0.000312	0.000596	CcSEcCtD
Risperidone—Breast disorder—Methotrexate—lymphatic system cancer	0.000311	0.000593	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000309	0.00059	CcSEcCtD
Risperidone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000308	0.000588	CcSEcCtD
Risperidone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000305	0.000581	CcSEcCtD
Risperidone—Decreased appetite—Vincristine—lymphatic system cancer	0.000303	0.000578	CcSEcCtD
Risperidone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000303	0.000577	CcSEcCtD
Risperidone—Somnolence—Mitoxantrone—lymphatic system cancer	0.000302	0.000576	CcSEcCtD
Risperidone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000301	0.000574	CcSEcCtD
Risperidone—Feeling abnormal—Carmustine—lymphatic system cancer	0.000301	0.000574	CcSEcCtD
Risperidone—Fatigue—Vincristine—lymphatic system cancer	0.000301	0.000573	CcSEcCtD
Risperidone—Asthenia—Bleomycin—lymphatic system cancer	0.0003	0.000573	CcSEcCtD
Risperidone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000299	0.00057	CcSEcCtD
Risperidone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000299	0.00057	CcSEcCtD
Risperidone—Constipation—Vincristine—lymphatic system cancer	0.000298	0.000569	CcSEcCtD
Risperidone—Pain—Vincristine—lymphatic system cancer	0.000298	0.000569	CcSEcCtD
Risperidone—Asthma—Methotrexate—lymphatic system cancer	0.000297	0.000567	CcSEcCtD
Risperidone—Pruritus—Bleomycin—lymphatic system cancer	0.000296	0.000565	CcSEcCtD
Risperidone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000295	0.000563	CcSEcCtD
Risperidone—Fatigue—Mitoxantrone—lymphatic system cancer	0.000293	0.000558	CcSEcCtD
Risperidone—Pancreatitis—Methotrexate—lymphatic system cancer	0.000292	0.000556	CcSEcCtD
Risperidone—Pain—Mitoxantrone—lymphatic system cancer	0.00029	0.000554	CcSEcCtD
Risperidone—Constipation—Mitoxantrone—lymphatic system cancer	0.00029	0.000554	CcSEcCtD
Risperidone—Body temperature increased—Carmustine—lymphatic system cancer	0.000289	0.000551	CcSEcCtD
Risperidone—Abdominal pain—Carmustine—lymphatic system cancer	0.000289	0.000551	CcSEcCtD
Risperidone—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000285	0.000544	CcSEcCtD
Risperidone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000285	0.000544	CcSEcCtD
Risperidone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00028	0.000534	CcSEcCtD
Risperidone—Neutropenia—Methotrexate—lymphatic system cancer	0.000278	0.000531	CcSEcCtD
Risperidone—Dysuria—Methotrexate—lymphatic system cancer	0.000278	0.000531	CcSEcCtD
Risperidone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000278	0.00053	CcSEcCtD
Risperidone—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000276	0.000527	CcSEcCtD
Risperidone—Abdominal pain—Vincristine—lymphatic system cancer	0.000276	0.000526	CcSEcCtD
Risperidone—Body temperature increased—Vincristine—lymphatic system cancer	0.000276	0.000526	CcSEcCtD
Risperidone—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000274	0.000523	CcSEcCtD
Risperidone—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000271	0.000518	CcSEcCtD
Risperidone—Urticaria—Mitoxantrone—lymphatic system cancer	0.00027	0.000514	CcSEcCtD
Risperidone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000269	0.000513	CcSEcCtD
Risperidone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000268	0.000512	CcSEcCtD
Risperidone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000268	0.000512	CcSEcCtD
Risperidone—Pneumonia—Methotrexate—lymphatic system cancer	0.000267	0.000509	CcSEcCtD
Risperidone—Vomiting—Bleomycin—lymphatic system cancer	0.000266	0.000507	CcSEcCtD
Risperidone—Infestation—Methotrexate—lymphatic system cancer	0.000265	0.000506	CcSEcCtD
Risperidone—Infestation NOS—Methotrexate—lymphatic system cancer	0.000265	0.000506	CcSEcCtD
Risperidone—Drowsiness—Methotrexate—lymphatic system cancer	0.000265	0.000506	CcSEcCtD
Risperidone—Depression—Methotrexate—lymphatic system cancer	0.000264	0.000504	CcSEcCtD
Risperidone—Rash—Bleomycin—lymphatic system cancer	0.000264	0.000503	CcSEcCtD
Risperidone—Dermatitis—Bleomycin—lymphatic system cancer	0.000264	0.000503	CcSEcCtD
Risperidone—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000263	0.000502	CcSEcCtD
Risperidone—Asthenia—Carmustine—lymphatic system cancer	0.000262	0.0005	CcSEcCtD
Risperidone—Renal failure—Methotrexate—lymphatic system cancer	0.000261	0.000497	CcSEcCtD
Risperidone—Stomatitis—Methotrexate—lymphatic system cancer	0.000258	0.000493	CcSEcCtD
Risperidone—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000258	0.000492	CcSEcCtD
Risperidone—Hypersensitivity—Vincristine—lymphatic system cancer	0.000257	0.00049	CcSEcCtD
Risperidone—Sweating—Methotrexate—lymphatic system cancer	0.000254	0.000485	CcSEcCtD
Risperidone—Haematuria—Methotrexate—lymphatic system cancer	0.000253	0.000482	CcSEcCtD
Risperidone—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000251	0.000478	CcSEcCtD
Risperidone—Epistaxis—Methotrexate—lymphatic system cancer	0.00025	0.000477	CcSEcCtD
Risperidone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00025	0.000477	CcSEcCtD
Risperidone—Asthenia—Vincristine—lymphatic system cancer	0.00025	0.000477	CcSEcCtD
Risperidone—Diarrhoea—Carmustine—lymphatic system cancer	0.00025	0.000477	CcSEcCtD
Risperidone—Nausea—Bleomycin—lymphatic system cancer	0.000248	0.000474	CcSEcCtD
Risperidone—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000247	0.000472	CcSEcCtD
Risperidone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000244	0.000465	CcSEcCtD
Risperidone—Dizziness—Carmustine—lymphatic system cancer	0.000241	0.000461	CcSEcCtD
Risperidone—Haemoglobin—Methotrexate—lymphatic system cancer	0.000239	0.000456	CcSEcCtD
Risperidone—Diarrhoea—Vincristine—lymphatic system cancer	0.000238	0.000455	CcSEcCtD
Risperidone—Hepatitis—Methotrexate—lymphatic system cancer	0.000238	0.000454	CcSEcCtD
Risperidone—Haemorrhage—Methotrexate—lymphatic system cancer	0.000238	0.000454	CcSEcCtD
Risperidone—Pharyngitis—Methotrexate—lymphatic system cancer	0.000236	0.000451	CcSEcCtD
Risperidone—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000235	0.000448	CcSEcCtD
Risperidone—Urethral disorder—Methotrexate—lymphatic system cancer	0.000233	0.000445	CcSEcCtD
Risperidone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000232	0.000443	CcSEcCtD
Risperidone—Vomiting—Carmustine—lymphatic system cancer	0.000232	0.000443	CcSEcCtD
Risperidone—Dizziness—Vincristine—lymphatic system cancer	0.00023	0.00044	CcSEcCtD
Risperidone—Rash—Carmustine—lymphatic system cancer	0.00023	0.000439	CcSEcCtD
Risperidone—Dermatitis—Carmustine—lymphatic system cancer	0.00023	0.000439	CcSEcCtD
Risperidone—Visual impairment—Methotrexate—lymphatic system cancer	0.000229	0.000438	CcSEcCtD
Risperidone—Headache—Carmustine—lymphatic system cancer	0.000229	0.000436	CcSEcCtD
Risperidone—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000225	0.000429	CcSEcCtD
Risperidone—Eye disorder—Methotrexate—lymphatic system cancer	0.000222	0.000424	CcSEcCtD
Risperidone—Tinnitus—Methotrexate—lymphatic system cancer	0.000222	0.000423	CcSEcCtD
Risperidone—Vomiting—Vincristine—lymphatic system cancer	0.000222	0.000423	CcSEcCtD
Risperidone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000221	0.000421	CcSEcCtD
Risperidone—Rash—Vincristine—lymphatic system cancer	0.00022	0.000419	CcSEcCtD
Risperidone—Dermatitis—Vincristine—lymphatic system cancer	0.00022	0.000419	CcSEcCtD
Risperidone—Headache—Vincristine—lymphatic system cancer	0.000218	0.000417	CcSEcCtD
Risperidone—Nausea—Carmustine—lymphatic system cancer	0.000217	0.000414	CcSEcCtD
Risperidone—Angiopathy—Methotrexate—lymphatic system cancer	0.000216	0.000412	CcSEcCtD
Risperidone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000216	0.000412	CcSEcCtD
Risperidone—Immune system disorder—Methotrexate—lymphatic system cancer	0.000215	0.00041	CcSEcCtD
Risperidone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000215	0.000409	CcSEcCtD
Risperidone—Rash—Mitoxantrone—lymphatic system cancer	0.000214	0.000408	CcSEcCtD
Risperidone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000214	0.000408	CcSEcCtD
Risperidone—Chills—Methotrexate—lymphatic system cancer	0.000214	0.000407	CcSEcCtD
Risperidone—Headache—Mitoxantrone—lymphatic system cancer	0.000213	0.000406	CcSEcCtD
Risperidone—Alopecia—Methotrexate—lymphatic system cancer	0.00021	0.000401	CcSEcCtD
Risperidone—Mental disorder—Methotrexate—lymphatic system cancer	0.000209	0.000398	CcSEcCtD
Risperidone—Erythema—Methotrexate—lymphatic system cancer	0.000207	0.000395	CcSEcCtD
Risperidone—Malnutrition—Methotrexate—lymphatic system cancer	0.000207	0.000395	CcSEcCtD
Risperidone—Nausea—Vincristine—lymphatic system cancer	0.000207	0.000395	CcSEcCtD
Risperidone—Dysgeusia—Methotrexate—lymphatic system cancer	0.000203	0.000387	CcSEcCtD
Risperidone—Nausea—Mitoxantrone—lymphatic system cancer	0.000202	0.000385	CcSEcCtD
Risperidone—Back pain—Methotrexate—lymphatic system cancer	0.0002	0.000382	CcSEcCtD
Risperidone—Vision blurred—Methotrexate—lymphatic system cancer	0.000195	0.000373	CcSEcCtD
Risperidone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000192	0.000367	CcSEcCtD
Risperidone—Anaemia—Methotrexate—lymphatic system cancer	0.000192	0.000365	CcSEcCtD
Risperidone—Malaise—Methotrexate—lymphatic system cancer	0.000187	0.000357	CcSEcCtD
Risperidone—Vertigo—Methotrexate—lymphatic system cancer	0.000186	0.000355	CcSEcCtD
Risperidone—Leukopenia—Methotrexate—lymphatic system cancer	0.000185	0.000354	CcSEcCtD
Risperidone—Cough—Methotrexate—lymphatic system cancer	0.000181	0.000345	CcSEcCtD
Risperidone—Convulsion—Methotrexate—lymphatic system cancer	0.00018	0.000343	CcSEcCtD
Risperidone—Chest pain—Methotrexate—lymphatic system cancer	0.000176	0.000337	CcSEcCtD
Risperidone—Myalgia—Methotrexate—lymphatic system cancer	0.000176	0.000337	CcSEcCtD
Risperidone—Arthralgia—Methotrexate—lymphatic system cancer	0.000176	0.000337	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000175	0.000334	CcSEcCtD
Risperidone—Discomfort—Methotrexate—lymphatic system cancer	0.000174	0.000333	CcSEcCtD
Risperidone—Confusional state—Methotrexate—lymphatic system cancer	0.000171	0.000325	CcSEcCtD
Risperidone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000169	0.000323	CcSEcCtD
Risperidone—Infection—Methotrexate—lymphatic system cancer	0.000168	0.000321	CcSEcCtD
Risperidone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000166	0.000316	CcSEcCtD
Risperidone—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000166	0.000316	CcSEcCtD
Risperidone—Skin disorder—Methotrexate—lymphatic system cancer	0.000164	0.000313	CcSEcCtD
Risperidone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000164	0.000312	CcSEcCtD
Risperidone—Anorexia—Methotrexate—lymphatic system cancer	0.000161	0.000308	CcSEcCtD
Risperidone—Hypotension—Methotrexate—lymphatic system cancer	0.000158	0.000301	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000154	0.000294	CcSEcCtD
Risperidone—Insomnia—Methotrexate—lymphatic system cancer	0.000153	0.000292	CcSEcCtD
Risperidone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000152	0.00029	CcSEcCtD
Risperidone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000151	0.000288	CcSEcCtD
Risperidone—Somnolence—Methotrexate—lymphatic system cancer	0.00015	0.000287	CcSEcCtD
Risperidone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000149	0.000284	CcSEcCtD
Risperidone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000147	0.00028	CcSEcCtD
Risperidone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000146	0.000279	CcSEcCtD
Risperidone—Fatigue—Methotrexate—lymphatic system cancer	0.000146	0.000278	CcSEcCtD
Risperidone—Pain—Methotrexate—lymphatic system cancer	0.000145	0.000276	CcSEcCtD
Risperidone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000139	0.000266	CcSEcCtD
Risperidone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000138	0.000264	CcSEcCtD
Risperidone—Urticaria—Methotrexate—lymphatic system cancer	0.000134	0.000256	CcSEcCtD
Risperidone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000134	0.000255	CcSEcCtD
Risperidone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000134	0.000255	CcSEcCtD
Risperidone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000125	0.000238	CcSEcCtD
Risperidone—Asthenia—Methotrexate—lymphatic system cancer	0.000121	0.000231	CcSEcCtD
Risperidone—Pruritus—Methotrexate—lymphatic system cancer	0.00012	0.000228	CcSEcCtD
Risperidone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000116	0.000221	CcSEcCtD
Risperidone—Dizziness—Methotrexate—lymphatic system cancer	0.000112	0.000213	CcSEcCtD
Risperidone—Vomiting—Methotrexate—lymphatic system cancer	0.000108	0.000205	CcSEcCtD
Risperidone—Rash—Methotrexate—lymphatic system cancer	0.000107	0.000203	CcSEcCtD
Risperidone—Dermatitis—Methotrexate—lymphatic system cancer	0.000107	0.000203	CcSEcCtD
Risperidone—Headache—Methotrexate—lymphatic system cancer	0.000106	0.000202	CcSEcCtD
Risperidone—Nausea—Methotrexate—lymphatic system cancer	0.0001	0.000192	CcSEcCtD
